Kruger E - Search Results

1

Endothelial monocyte activating polypeptide II induces endothelial cell apoptosis and may inhibit tumor angiogenesis.

Berger AC, Alexander HR, Tang G, Wu PS, Hewitt SM, Turner E, Kruger E, Figg WD, Grove A, Kohn E, Stern D, Libutti SK. Berger AC, et al. Among authors: kruger e. Microvasc Res. 2000 Jul;60(1):70-80. doi: 10.1006/mvre.2000.2249. Microvasc Res. 2000. PMID: 10873516

2

UCN-01, a protein kinase C inhibitor, inhibits endothelial cell proliferation and angiogenic hypoxic response.

Kruger EA, Blagosklonny MV, Dixon SC, Figg WD. Kruger EA, et al. Invasion Metastasis. 1998-1999;18(4):209-18. doi: 10.1159/000024514. Invasion Metastasis. 1998. PMID: 10640907

3

The angiogenesis inhibitor, endostatin, does not affect murine cutaneous wound healing.

Berger AC, Feldman AL, Gnant MF, Kruger EA, Sim BK, Hewitt S, Figg WD, Alexander HR, Libutti SK. Berger AC, et al. Among authors: kruger ea. J Surg Res. 2000 Jun 1;91(1):26-31. doi: 10.1006/jsre.2000.5890. J Surg Res. 2000. PMID: 10816345

4

5'-OH-thalidomide, a metabolite of thalidomide, inhibits angiogenesis.

Price DK, Ando Y, Kruger EA, Weiss M, Figg WD. Price DK, et al. Ther Drug Monit. 2002 Feb;24(1):104-10. doi: 10.1097/00007691-200202000-00017. Ther Drug Monit. 2002. PMID: 11805730

5

Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer.

Figg WD, Kruger EA, Price DK, Kim S, Dahut WD. Figg WD, et al. Invest New Drugs. 2002 May;20(2):183-94. doi: 10.1023/a:1015626410273. Invest New Drugs. 2002. PMID: 12099578 Review.

6

Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues.

Ng SS, Gütschow M, Weiss M, Hauschildt S, Teubert U, Hecker TK, Luzzio FA, Kruger EA, Eger K, Figg WD. Ng SS, et al. Cancer Res. 2003 Jun 15;63(12):3189-94. Cancer Res. 2003. PMID: 12810647

7

Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells.

Dixon SC, Kruger EA, Bauer KS, Figg WD. Dixon SC, et al. Among authors: kruger ea. Cancer Chemother Pharmacol. 1999;43 Suppl:S78-84. doi: 10.1007/s002800051103. Cancer Chemother Pharmacol. 1999. PMID: 10357564

8

Carboxyamido-triazole inhibits angiogenesis by blocking the calcium-mediated nitric-oxide synthase-vascular endothelial growth factor pathway.

Bauer KS, Cude KJ, Dixon SC, Kruger EA, Figg WD. Bauer KS, et al. Among authors: kruger ea. J Pharmacol Exp Ther. 2000 Jan;292(1):31-7. J Pharmacol Exp Ther. 2000. PMID: 10604929

9

Endostatin inhibits microvessel formation in the ex vivo rat aortic ring angiogenesis assay.

Kruger EA, Duray PH, Tsokos MG, Venzon DJ, Libutti SK, Dixon SC, Rudek MA, Pluda J, Allegra C, Figg WD. Kruger EA, et al. Biochem Biophys Res Commun. 2000 Feb 5;268(1):183-91. doi: 10.1006/bbrc.1999.2018. Biochem Biophys Res Commun. 2000. PMID: 10652234

10

TNP-470: an angiogenesis inhibitor in clinical development for cancer.

Kruger EA, Figg WD. Kruger EA, et al. Expert Opin Investig Drugs. 2000 Jun;9(6):1383-96. doi: 10.1517/13543784.9.6.1383. Expert Opin Investig Drugs. 2000. PMID: 11060750 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

784 results

Search Page

Filters